Xortx announces usd $925,000 private placement

Not for distribution to united states news wire services or for dissemination in the united states calgary, alberta, june 26, 2025 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces a non-brokered private placement to raise up to usd $925,000 through the issuance of up to 1,267,123 common share units of the company at a price of usd $0.73 per unit (the “offering”). each unit will comprise one common share and one common share purchase warrant (a “warrant”).
XRTX Ratings Summary
XRTX Quant Ranking